LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer
Metrics: PDF 630 views | HTML 1785 views | ?
Akihiro Miyazaki1,*, Hiromi Nakai1,*, Tomoko Sonoda2, Yoshihiko Hirohashi3, Mika K. Kaneko4, Yukinari Kato4,5, Yoshihiko Sawa6 and Hiroyoshi Hiratsuka1
1Department of Oral Surgery, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8543, Japan
2Department of Public Health, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8556, Japan
3Department of Pathology, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8556, Japan
4Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi 980-8575, Japan
5New Industry Creation Hatchery Center, Tohoku University, Aoba-ku, Sendai, Miyagi 980-8575, Japan
6Deparment of Oral Function & Anatomy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama Kita-ku 700-0914, Japan
*These authors have contributed equally to this work
Yoshihiko Sawa, email: firstname.lastname@example.org
Keywords: LpMab-23; predictor; podoplanin; tongue cancer; antibody
Received: October 17, 2017 Accepted: March 12, 2018 Published: April 20, 2018
Purpose: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer.
Patients and Methods: The association between LpMab-23-recognizing cancer-type PDPN expression and clinical/pathological features were analyzed on 60 patients with stage I and II tongue cancer treated with transoral resection of the primary tumor.
Results: In the mode of invasion, the LpMab-23-dull/negative cases were significantly larger in cases with low-grade malignancies and without late cervical lymph node metastasis, than in cases with high-grade malignancies and the metastasis. In the high-grade malignant cases, LpMab-23-positive cases were significantly larger than LpMab-23-dull/negative cases. The Kaplan–Meier curves of the five-year metastasis-free survival rate (MFS) were significantly lower in the LpMab-23 positive patients than in LpMab-23 dull/negative patients. The LpMab-23-dull/negative cases showed the highest MFS in all of the clinical/pathological features and particularly, the MFS of the LpMab-23 positive cases decreased to less than 60% in the first year. In the Cox proportional hazard regression models a comparison of the numbers of LpMab-23 dull/negative with positive cases showed the highest hazard ratio with statistical significance in all of the clinical/pathological features.
Conclusions: LpMab-23 positive cases may be considered to present a useful predictor of poor prognosis for early stage tongue cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.